Terms ending in 2029
Every in-force patent on Respivert Limited's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,293,748 | P38 Map Kinase Inhibitors In force · Medium confidence | Respivert Ltd. | In force | Medium confidence | |
| US 8,293,771 | P38 Map Kinase Inhibitors In force · Medium confidence | Respivert Ltd. | In force | Medium confidence | |
| US 8,975,285 | P38 Map Kinase Inhibitors In force · Medium confidence | Respivert Ltd. | In force | Medium confidence | |
| US 9,024,041 | P38 Map Kinase Inhibitors In force · Medium confidence | Respivert Ltd. | In force | Medium confidence | |
| US 9,260,410 | P38 Map Kinase Inhibitors In force · Medium confidence | Respivert Ltd. | In force | Medium confidence | |
| US 9,771,354 | Pyrazole P38 Map Kinase Inhibitors In force · Medium confidence | Respivert Limited | In force | Medium confidence | |
| US 8,299,073 | P38 Map Kinase Inhibitors In force · Medium confidence | Respivert Ltd. | In force | Medium confidence | |
| US 9,242,960 | P38MAP Kinase Inhibitors In force · Medium confidence | Respivert Ltd. | In force | Medium confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.